Document 0101
 DOCN  M95B0101
 TI    Equal IgG antibody response to pneumococcal vaccination in all stages of
       human immunodeficiency virus disease.
 DT    9511
 AU    Vandenbruaene M; Colebunders R; Mascart-Lemone F; Haerden Y; Van Hove D;
       Peeters M; Goeman J; Van Royen P; Avonts D; Institute of Tropical
       Medicine, Antwerp, Belgium.
 SO    J Infect Dis. 1995 Aug;172(2):551-3. Unique Identifier : AIDSLINE
       MED/95348560
 AB    To evaluate the immunogenicity and safety of a 23-valent pneumococcal
       vaccine in human immunodeficiency virus (HIV)-seropositive patients, 80
       men and 18 women received 1 dose of the vaccine (Pneumo 23; Pasteur
       Merieux MSD, Brussels). The total IgG antibody response against all 23
       Streptococcus pneumoniae capsular antigens was measured. Antibody levels
       were expressed in arbitrary units per microliter, referring to a
       standard curve. Geometric mean titers of the total IgG capsular
       antibodies on the day of vaccination and 30-45 days later were compared.
       The ratios of titers after and before vaccination in patients with >
       500, 200-500, and < 200 CD4 lymphocytes/microL were 10, 10, and 12.6,
       respectively. Nonresponse (ratio < 4) occurred in 17% of patients and
       was unrelated to CD4 cell count. The vaccine was well tolerated; no
       serious side effects occurred. In 83% of the patients with HIV
       infection, the total antipneumococcal IgG level was higher after
       vaccination.
 DE    Adult  Antibody Formation  Bacterial Vaccines/*IMMUNOLOGY  CD4
       Lymphocyte Count  Female  Human  HIV Infections/*IMMUNOLOGY  HIV
       Seropositivity/IMMUNOLOGY  IgG/*BLOOD  Male  Streptococcus
       pneumoniae/*IMMUNOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).